Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Arch Toxicol ; 96(1): 377-386, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34767040

RESUMEN

Error-corrected sequences (ECSs) that utilize double-stranded DNA sequences are useful in detecting mutagen-induced mutations. However, relatively higher frequencies of G:C > T:A (1 × 10-7 bp) and G:C > C:G (2 × 10-7 bp) errors decrease the accuracy of detection of rare G:C mutations (approximately 10-7 bp). Oxidized guanines in single-strand (SS) overhangs generated after shearing could serve as the source of these errors. To remove these errors, we first computationally discarded up to 20 read bases corresponding to the ends of the DNA fragments. Error frequencies decreased proportionately with trimming length; however, the results indicated that they were not sufficiently removed. To efficiently remove SS overhangs, we evaluated three mechanistically distinct SS-specific nucleases (S1 Nuclease, mung bean nuclease, and RecJf exonuclease) and found that they were more efficient than computational trimming. Consequently, we established Jade-Seq™, an ECS protocol with S1 Nuclease treatment, which reduced G:C > T:A and G:C > C:G errors to 0.50 × 10-7 bp and 0.12 × 10-7 bp, respectively. This was probably because S1 Nuclease removed SS regions, such as gaps and nicks, depending on its wide substrate specificity. Subsequently, we evaluated the mutation-detection sensitivity of Jade-Seq™ using DNA samples from TA100 cells exposed to 3-methylcholanthrene and 7,12-dimethylbenz[a]anthracene, which contained the rare G:C > T:A mutation (i.e., 2 × 10-7 bp). Fold changes of G:C > T:A compared to the vehicle control were 1.2- and 1.3-times higher than those of samples without S1 Nuclease treatment, respectively. These findings indicate the potential of Jade-Seq™ for detecting rare mutations and determining the mutagenicity of environmental mutagens.


Asunto(s)
Secuenciación de Nucleótidos de Alto Rendimiento , Mutágenos , ADN , Reparación del ADN , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Mutágenos/toxicidad , Mutación
2.
Mutagenesis ; 36(3): 245-254, 2021 07 07.
Artículo en Inglés | MEDLINE | ID: mdl-33590004

RESUMEN

A precise understanding of differences in genomic mutations according to the mutagenic mechanisms detected in mutagenicity data is required to evaluate the carcinogenicity of environmental mutagens. Recently, we developed a highly accurate genome sequencing method, 'Hawk-Seq™', that enables the detection of mutagen-induced genome-wide mutations. However, its applicability to detect various mutagens and identify differences in mutational profiles is not well understood. Thus, we evaluated DNA samples from Salmonella typhimurium TA100 exposed to 11 mutagens, including alkylating agents, aldehydes, an aromatic nitro compound, epoxides, aromatic amines and polycyclic aromatic hydrocarbons (PAHs). We extensively analysed mutagen-induced mutational profiles and studied their association with the mechanisms of mutagens. Hawk-Seq™ sensitively detected mutations induced by all 11 mutagens, including one that increased the number of revertants by approximately 2-fold in the Ames test. Although the sensitivity for less water-soluble mutagens was relatively low, we increased the sensitivity to obtain high-resolution spectra by modifying the exposure protocol. Moreover, two epoxides indicated similar 6- or 96-dimensional mutational patterns; likewise, three SN1-type alkylating agents indicated similar mutational patterns, suggesting that the mutational patterns are compound category specific. Meanwhile, an SN2 type alkylating agent exhibited unique mutational patterns compared to those of the SN1 type alkylating agents. Although the mutational patterns induced by aldehydes, the aromatic nitro compound, aromatic amines and PAHs did not differ substantially from each other, the maximum total base substitution frequencies (MTSFs) were similar among mutagens in the same structural groups. Furthermore, the MTSF was found to be associated with the carcinogenic potency of some direct-acting mutagens. These results indicate that our method can generate high-resolution mutational profiles to identify characteristic features of each mutagen. The detailed mutational data obtained by Hawk-Seq™ can provide useful information regarding mutagenic mechanisms and help identify its association with the carcinogenicity of mutagens without requiring carcinogenicity data.


Asunto(s)
Análisis Mutacional de ADN/métodos , Pruebas de Mutagenicidad , Mutágenos/toxicidad , Salmonella typhimurium/efectos de los fármacos , Salmonella typhimurium/genética , Secuenciación Completa del Genoma/métodos , ADN Bacteriano , Genoma Bacteriano , Análisis de Componente Principal , Sensibilidad y Especificidad
3.
Arch Toxicol ; 93(9): 2689-2701, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31451845

RESUMEN

It is difficult to identify mutagen-induced genome-wide somatic mutations using next generation sequencing; hence, mutagenic features of each mutagen and their roles in cancer development require further elucidation. We described Hawk-Seq™, a highly accurate genome sequencing method and the optimal conditions, for using it to construct libraries that would enable the accurate (c.a. 1 error/107-108 bp) and efficient survey of genome-wide mutations. Genomic mutations in gpt delta mice or Salmonella typhimurium TA100 exposed to methylnitrosourea (MNU), ethylnitrosourea (ENU), diethylnitrosamine (DEN), benzo[a]pyrene (BP), and aristolochic acid (AA) were profiled using Hawk-Seq™ to analyse positions, substitution patterns, or frequencies. The resultant vast mutation data provided high-resolution mutational signatures, including for minor mutational fractions (e.g. G:C>A:T by AA), which enabled the clarification of the mutagenic features of all mutagens. The 96-type mutational signatures of MNU, AA, and BP indicate their partial similarity to signature 11, 22, and 4 or 29, respectively. Meanwhile, signatures attributable to ENU and DEN were highly similar to each other, but not to signature 11, suggesting that the mechanisms of these agents differed from those of typical alkylating agents. Thus, Hawk-Seq™ can clarify genome-wide chemical mutagenicity profiles at extraordinary resolutions, thereby providing insight into mutagen mechanisms and their roles in cancer development.


Asunto(s)
Estudio de Asociación del Genoma Completo/métodos , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Pruebas de Mutagenicidad/métodos , Mutágenos/toxicidad , Mutación/efectos de los fármacos , Animales , Proteínas de Escherichia coli/genética , Ratones Transgénicos , Mutágenos/química , Neoplasias/genética , Pentosiltransferasa/genética , Salmonella typhimurium/efectos de los fármacos , Salmonella typhimurium/genética
4.
J Appl Toxicol ; 37(9): 1125-1128, 2017 09.
Artículo en Inglés | MEDLINE | ID: mdl-28397974

RESUMEN

Next-generation sequencing (NGS) is a potentially useful technology to achieve a more precise evaluation of chemical mutagenicity. To establish NGS-based mutagenicity assays, which enable the direct detection of chemically induced mutations in a whole genome manner, the selection of appropriate biological resources and their precise genome sequences are essential. Here, we performed genome re-sequencing analyses of Salmonella typhimurium LT-2 strains TA98 and TA100, which have been frequently used in mutagenicity assays. We identified several strain-specific mutations including those that were relevant to their known phenotypes (his, ΔuvrB and rfa). The details of rfa mutations were first clarified in this study, which was a frameshift variant in rfaF and a missense variant in rfaC in TA98 and TA100, respectively. The uvrB deletion in TA98 was larger than that in TA100, which suggested differences in defects of lipopolysaccharide synthesis between these strains. The re-sequenced genome data of TA98 and TA100 will help us establish NGS-based bacterial mutagenicity assays and understand the biological events seen in them. Copyright © 2017 John Wiley & Sons, Ltd.


Asunto(s)
Genoma Bacteriano , Secuenciación de Nucleótidos de Alto Rendimiento , Pruebas de Mutagenicidad , Salmonella typhimurium/genética , Daño del ADN , ADN Bacteriano/genética , Mutación , Salmonella typhimurium/clasificación , Análisis de Secuencia de ADN
5.
Sci Rep ; 8(1): 9583, 2018 06 25.
Artículo en Inglés | MEDLINE | ID: mdl-29942026

RESUMEN

Trinucleotide mutational signatures extracted from cancer genomes provide clues useful in understanding the roles of mutagens and mutagenic mechanisms in cancer development. The lack of a simple method for genome-wide analysis of alterations induced by mutagens hampers the identification of trinucleotide signatures of mutagen exposure and evaluation of their relationships with human cancers. Here, we describe a novel approach to facilitate analysis of chemically induced mutations in bacterial cells by detection of increased frequencies of base substitutions after mutagen exposure, using paired-end overlapping next-generation sequencing. DNA samples from Salmonella typhimurium strain TA100, exposed to three alkylating agents, ethylnitrosourea (ENU), methylnitrosourea (MNU), and ethyl methansulphonate (EMS), were analysed. The G:C > A:T mutation frequency was increased in all samples, whereas A:T base pair substitution frequencies were increased specifically in samples exposed to ENU, consistent with previous reports. Mutation patterns in the context of 96 possible trinucleotide formats in these samples exhibited a sharp peak corresponding to an NpCpY consensus sequence, which is similar to the mutational signature of alkylating agents in human cancer. These results indicate that our approach can be useful in facilitating the understanding of mechanisms underlying chemical mutagenicity and for identification of unknown causal mutagens in human cancer.


Asunto(s)
Análisis Mutacional de ADN , Genómica , Secuenciación de Nucleótidos de Alto Rendimiento , Mutágenos/toxicidad , ADN Bacteriano/genética , Salmonella typhimurium/efectos de los fármacos , Salmonella typhimurium/genética
6.
Food Chem Toxicol ; 106(Pt A): 185-192, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28465188

RESUMEN

Alpha-linolenic acid (ALA)-enriched diacylglycerol (DAG) oil is an edible oil enriched with DAG (>80%) and ALA (>50%). The present study investigated whether ALA-DAG oil promotes tumorigenesis in the tongue and gastrointestinal tract, using a rat medium-term multi-organ carcinogenesis bioassay model. Rats were treated with five genotoxic carcinogens to induce multi-organ tumorigenesis until week 4, and from 1 week after withdrawal, fed a semi-synthetic diet (AIN-93G) containing ALA-DAG oil at concentrations of 0, 13,750, 27,500, and 55,000 ppm. Rats fed AIN-93G containing 55,000 ppm ALA-triacylglycerol or a standard basal diet served as reference and negative control groups, respectively. Animals were euthanized at week 30. ALA-DAG oil was shown to have no effects on survival, general condition, body weight, food consumption, or organ weight. More discolored spots were observed in the stomachs of the 13,750- and 55,000-ppm ALA-DAG groups than in those of the control groups; however, there were no differences in the frequency of histopathological findings across groups. There were no meaningful increases in the incidence of pre-neoplastic and neoplastic lesions in the tongue and gastrointestinal tract among the groups. We therefore conclude that ALA-DAG oil does not promote tumor development in the digestive system.


Asunto(s)
Diglicéridos/farmacología , Tracto Gastrointestinal/efectos de los fármacos , Lengua/efectos de los fármacos , Ácido alfa-Linolénico/farmacología , Animales , Bioensayo , Pruebas de Carcinogenicidad , Diglicéridos/análisis , Tracto Gastrointestinal/patología , Masculino , Ratas , Ratas Endogámicas F344 , Lengua/patología , Ácido alfa-Linolénico/análisis
7.
Artículo en Inglés | MEDLINE | ID: mdl-27169375

RESUMEN

New OECD test guidelines have been issued, in which the cytotoxicity index relative cell count (RCC) is replaced with a new index, RICC or RPD (relative increase in cell count/relative population doubling), with the goal of reducing the high proportion of false positive results in in vitro chromosomal aberration tests. Using a mathematical approach to estimate new indices from the RCC, we constructed an evaluation flow that quantitatively estimates how often the previous test conclusions change when applying the updated cytotoxicity criteria. The new evaluation flow was applied to a retrospective evaluation of 285 chemicals in two databases. The effects of the employment of new cytotoxicity indices are investigated at a large scale. Using the new evaluation flow, 90 chemicals were estimated as positive, 39 were designated as estimated negative (13 probably negative and 26 possibly negative), and 140 were designated as negative. Moreover, we also applied a prioritization index to indicate the likelihood of a chemical being re-evaluated as negative and assigned priorities for testing. Most of the chemicals that were designated as estimated negative and had negative results in the in vivo micronucleus tests were considered as false-positives that would be correctly judged under the new test guideline. Furthermore, statistical analysis of the frequency of estimated negatives revealed that the results for Ames-positive chemicals, especially those with a strong response, are unlikely to change. Therefore, we concluded that the new indices would likely reduce the proportion of false positive results and not increase the proportion of false negative results. This study is the first report of a comprehensive re-evaluation of test results in terms of new cytotoxicity indices. The evaluation flow we have developed facilitates efficient retrospective evaluation of genotoxicity.


Asunto(s)
Aberraciones Cromosómicas/inducido químicamente , Pruebas de Mutagenicidad/normas , Mutágenos/toxicidad , Animales , Células CHO , Cricetulus , Daño del ADN/efectos de los fármacos , Pruebas de Micronúcleos , Estudios Retrospectivos
8.
Mutat Res Genet Toxicol Environ Mutagen ; 780-781: 76-80, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25892626

RESUMEN

The in vivo genotoxicity of CI Solvent Yellow 14 (Sudan I) was examined using repeated-dose liver and gastrointestinal tract micronucleus (MN) assays in young adult rats. Sudan I is a mono-azo dye based on aniline and 1-amino-2-hydroxynaphthalene. This dye was demonstrated as a rat liver carcinogen in a National Toxicology Program (NTP) bioassay, and genotoxicity was noted in a rat bone marrow micronucleus (BMMN) assay. In the present study, Sudan I was administered orally to rats for 14-days, and the MN frequency in the liver, stomach, colon, and bone marrow were analyzed. The frequency of micronucleated hepatocytes (MNHEPs) was not significantly increased by the administration of the Sudan I. Gastrointestinal tract MNs were also not induced. However, in the BMMN assay, a significant increase in micronucleated immature erythrocytes (MNIMEs) was observed in a dose-dependent manner. While Sudan I has been reported to lack hepatic genotoxicity, it has also exhibited tumor-promoting activities. These results are consistent with the lack of induction of MN in the hepatocytes. The lack of MN induction in cells of the gastrointestinal tract was also logical because azo-compounds are reported to be unlikely to induce DNA damage in the rat gut. The repeated-dose rat liver and gastrointestinal tract MN assays have the potential to be used in the evaluation of the genotoxicity of a chemical in each organ in accordance with its mode of action.


Asunto(s)
Médula Ósea/efectos de los fármacos , Carcinógenos/toxicidad , Pruebas de Micronúcleos , Naftoles/toxicidad , Reticulocitos/efectos de los fármacos , Administración Oral , Factores de Edad , Animales , Peso Corporal/efectos de los fármacos , Médula Ósea/patología , Aberraciones Cromosómicas/efectos de los fármacos , Colon/efectos de los fármacos , Conducta Cooperativa , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Hepatocitos/efectos de los fármacos , Humanos , Japón , Hígado/efectos de los fármacos , Masculino , Especificidad de Órganos , Ratas , Ratas Sprague-Dawley , Reticulocitos/patología , Sociedades Farmacéuticas , Estómago/efectos de los fármacos
9.
Artículo en Inglés | MEDLINE | ID: mdl-25892619

RESUMEN

The repeated-dose liver micronucleus (RDLMN) assay using young adult rats has the potential to detect hepatocarcinogens. We conducted a collaborative study to assess the performance of this assay and to evaluate the possibility of integrating it into general toxicological studies. Twenty-four testing laboratories belonging to the Mammalian Mutagenicity Study Group, a subgroup of the Japanese Environmental Mutagen Society, participated in this trial. Twenty-two model chemicals, including some hepatocarcinogens, were tested in 14- and/or 28-day RDLMN assays. As a result, 14 out of the 16 hepatocarcinogens were positive, including 9 genotoxic hepatocarcinogens, which were reported negative in the bone marrow/peripheral blood micronucleus (MN) assay by a single treatment. These outcomes show the high sensitivity of the RDLMN assay to hepatocarcinogens. Regarding the specificity, 4 out of the 6 non-liver targeted genotoxic carcinogens gave negative responses. This shows the high organ specificity of the RDLMN assay. In addition to the RDLMN assay, we simultaneously conducted gastrointestinal tract MN assays using 6 of the above carcinogens as an optional trial of the collaborative study. The MN assay using the glandular stomach, which is the first contact site of the test chemical when administered by oral gavage, was able to detect chromosomal aberrations with 3 test chemicals including a stomach-targeted carcinogen. The treatment regime was the 14- and/or 28-day repeated-dose, and the regime is sufficiently promising to incorporate these methods into repeated-dose toxicological studies. The outcomes of our collaborative study indicated that the new techniques to detect chromosomal aberrations in vivo in several tissues worked successfully.


Asunto(s)
Carcinógenos/toxicidad , Tracto Gastrointestinal/efectos de los fármacos , Sustancias Peligrosas/toxicidad , Hepatocitos/efectos de los fármacos , Hígado/efectos de los fármacos , Pruebas de Micronúcleos , Factores de Edad , Animales , Médula Ósea/efectos de los fármacos , Aberraciones Cromosómicas/efectos de los fármacos , Conducta Cooperativa , Daño del ADN , Esquema de Medicación , Femenino , Humanos , Japón , Masculino , Especificidad de Órganos , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Reticulocitos/efectos de los fármacos , Sensibilidad y Especificidad , Sociedades Farmacéuticas
10.
Anticancer Res ; 32(8): 3097-101, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22843879

RESUMEN

BACKGROUND: Protein kinase C (PKC)α is distributed in almost all tissues and participates in various signaling pathways. However, the role of PKCα in carcinogenesis remains unclear. In this study, we performed complete skin carcinogenesis in PKCα knockout mice by repeated administration of 7,12-dimethylbenz[a]anthracene (DMBA). MATERIALS AND METHODS: Complete skin carcinogenesis was performed by repeated DMBA treatment using PKCα knockout mice. The number of tumors was determined weekly. Tumor types were determined by Hematoxylin and eosin (H & E) analysis. Tumor growth was assayed by proliferating cell nuclear antigen (PCNA) staining. RESULTS: In the knockout mice, the average number of tumors was 16.6/mouse at 20 weeks. In contrast, in the wild-type (WT) mice, the tumor number was 6.9/mouse. Growth and malignant grade of tumors in PKCα knockout mice did not differ from those in WT mice. CONCLUSION: PKCα suppresses tumor formation, but not tumor growth and progression in skin carcinogenesis.


Asunto(s)
Transformación Celular Neoplásica/metabolismo , Proteína Quinasa C-alfa/metabolismo , Neoplasias Cutáneas/enzimología , 9,10-Dimetil-1,2-benzantraceno/toxicidad , Animales , Carcinógenos/toxicidad , Transformación Celular Neoplásica/genética , Femenino , Ratones , Ratones Noqueados , Neoplasias Cutáneas/inducido químicamente , Neoplasias Cutáneas/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA